Thonzonium bromide is an antibacterial agent and monocationic surface-active agent that inhibits RANKL-induced osteoclast formation and bone resorption in vitro. It prevents LPS-induced bone loss in vivo by blocking RANKL-induced activation of NF-κB, ERK, c-Fos, and NFATc1, which are crucial for osteoclast formation. Additionally, it disrupts F-actin ring formation in mature osteoclasts and inhibits proton transport in a dose-dependent manner.
- Inhibits RANKL-induced osteoclast formation
- Prevents LPS-induced bone loss in vivo
- Blocks key signaling pathways for osteoclast formation
- Disrupts F-actin ring formation in mature osteoclasts
- Inhibits proton transport